Expert Interview
Comparing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Ticker(s): EYPT, REGN, FDMTInstitution: Retina Associates of New York
- Private practice ophthalmologist who also trains doctors at the New York Eye and Ear Infirmary of Mount Sinai.
- Currently manages between 200-300 patients with wet-AMD and 200 with geographic atrophy.
- Has authored multiple peer-reviewed publications, including research on macular degeneration, diabetic retinopathy, macular pucker, and unusual diseases of the retina.
Please describe your background and current practice setting
Added By: ben_adminHow many patients with macular edema do you currently treat monthly?
Added By: ben_adminCan you break down your treatment algorithm? What are you using in the first and second line for these indications?
Added By: ben_adminWhat were your overall impressions of Eyepoint's phase 1 data for treatment of patients with wet-AMD? Of 4D's gene therapy?
Added By: ben_adminPlease rank your excitement for Eyepoint's EYP-1901 and 4D Molecular Therapeutics 4D-150 on a scale of 1-10
Added By: ben_adminWhen 4D announces its wet-AMD data on all 15 pa at ARVO 23, what specific data would you like to see to conclude this program is best in class?
Added By: user433d8c57What efficay, safety profile, and duration of response do you need to see from a gene therapy treatment to prescribe it broadly in practice? What % of wetAMD patients in your practice would you likely treat with gene therapy?
Do you have any relationship with EYPT or FDMT?
Added By: user433d8c57What are your thoughts around neuroprotection and fibrosis?
Added By: kp815Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
